Imugene Limited (AU:IMU)

Imugene Limited (IMU) Share Price & Analysis


IMU Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.21
Previous CloseAU$0.05
Average Volume (3M)32.52M
Market Cap
Enterprise ValueAU$242.50M
Total Cash (Recent Filing)AU$99.89M
Total Debt (Recent Filing)AU$673.43K
Price to Earnings (P/E)-8.1
Feb 28, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,834,259,350
10 Day Avg. Volume34,707,258
30 Day Avg. Volume32,519,621
Standard Deviation0.29
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0




What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest share price was AU$0.05 and its highest was AU$0.21 in the past 12 months.
    What is Imugene Limited’s market cap?
    Currently, no data Available
    When is Imugene Limited’s upcoming earnings report date?
    Imugene Limited’s upcoming earnings report date is Feb 28, 2024 which is in 157 days.
      How were Imugene Limited’s earnings last quarter?
      Imugene Limited released its earnings results on Aug 25, 2023. The company reported AU$0 earnings per share for the quarter, the consensus estimate of AU$0 by AU$0.
        Is Imugene Limited overvalued?
        According to Wall Street analysts Imugene Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Imugene Limited pay dividends?
          Imugene Limited does not currently pay dividends.
          What is Imugene Limited’s EPS estimate?
          Imugene Limited’s EPS estimate is AU$0.
            How many shares outstanding does Imugene Limited have?
            Imugene Limited has 6,834,259,300 shares outstanding.
              What happened to Imugene Limited’s price movement after its last earnings report?
              Imugene Limited reported an EPS of AU$0 in its last earnings report, expectations of AU$0. Following the earnings report the stock price went down -2.817%.
                Which hedge fund is a major shareholder of Imugene Limited?
                Currently, no hedge funds are holding shares in AU:IMU


                Imugene Limited Stock Smart Score

                The Imugene Limited Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Imugene Limited

                Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.


                Top 5 ETFs holding IMU

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold IMU. The ETFs are listed according to market value of IMU within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Onconova Therapeutics
                Cyclacel Pharmaceuticals
                Imugene Limited

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis